OTLK - Outlook Therapeutics, Inc.
IEX Last Trade
1.65
0.005 0.303%
Share volume: 16,392
Last Updated: Thu 26 Dec 2024 08:29:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.64
0.00
0.30%
Fundamental analysis
31%
Profitability
50%
Dept financing
25%
Liquidity
18%
Performance
16%
Performance
5 Days
3.52%
1 Month
-69.94%
3 Months
-74.12%
6 Months
-79.44%
1 Year
-83.52%
2 Year
36.11%
Key data
Stock price
$1.65
DAY RANGE
$1.46 - $1.66
52 WEEK RANGE
$0.46 - $12.85
52 WEEK CHANGE
-$82.77
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: C. Russell Trenary
Region: US
Website: outlooktherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: outlooktherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Recent news